← Oncology Approval Tracker

FDA DECISION ·

Emend for injection

fosaprepitant · Merck

FDA approvalNew dosing regimenChemotherapy-induced nausea and vomiting
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A three-day dosing option for prevention of chemotherapy-induced nausea and vomiting in eligible pediatric patients using intravenous Emend on day one.

LAMPGEN ANALYSIS

Why it matters

The supplemental decision adds an administration option for pediatric antiemetic prophylaxis.

What research teams should watch

Confirm the pediatric regimen and schedule all three days of antiemetic coverage around chemotherapy.

PRIMARY RECORDS

Sources